Rhia Ventures

Eli is a company focused on empowering women to manage their health by providing insights into their hormone profiles. It has developed an at-home device that monitors hormones using saliva samples, allowing for daily tracking of hormonal changes. Alongside the device, Eli offers an app that delivers personalized insights based on the collected data. The primary aim of Eli is to offer women a reliable and effective means to take charge of their fertility and contraception choices, thereby enhancing their overall health and well-being.

TwentyEight Health, Inc. is a Brooklyn-based company founded in 2018 that focuses on providing a digital healthcare platform for women's reproductive and sexual health. The platform offers online doctor evaluations for birth control prescriptions, quick home deliveries of medications, and secure messaging with healthcare professionals. By prioritizing accessibility, TwentyEight Health aims to serve underserved women, particularly Medicaid recipients, and to revolutionize the way they access inclusive and high-quality health services. The company's innovative approach to telemedicine and care coordination facilitates a more convenient and affordable means for women to manage their health needs.

Contraline, Inc. is a biotechnology company based in Charlottesville, Virginia, focused on developing innovative male birth control solutions. The company is pioneering the first long-lasting, non-hormonal, and reversible contraceptive for men. Its primary product, Echo-V, is an ultrasound-visible polymer solution that is injected into the vas deferens, forming a polymer hydrogel device. This device functions as a semi-permeable membrane, effectively blocking sperm while allowing bodily fluids to pass through. Contraline also offers Vasintomy, a non-surgical procedure for the insertion of Echo-V, providing a cost-effective and accessible approach to male contraception. Incorporated in 2015, Contraline aims to transform the landscape of reproductive health for men.

AOA, based in Boston, New York, and London, is a female-led company focused on developing innovative cancer diagnostics specifically for women's health. The company is dedicated to creating the first accurate early-stage liquid biopsy test for ovarian cancer, which aims to enhance clinical practices, reduce patient mortality, and offer cost savings for healthcare payers. Utilizing an artificial intelligence-enabled platform, AOA's technology analyzes tumor marker gangliosides to facilitate the early detection of ovarian cancer. This approach not only helps healthcare providers implement more effective treatment strategies but also ensures that patients can access life-saving treatments sooner and at a more affordable cost.

YourChoice Therapeutics, Inc. is a biotechnology company based in Berkeley, California, founded in 2018. The company focuses on developing non-hormonal contraceptive products aimed at providing women with safe and effective birth control options. Its innovative technology is based on the concept of a "molecular condom," which utilizes an active compound to inhibit sperm motility, thereby preventing sperm from fertilizing the egg. This approach seeks to eliminate the risks and side effects commonly associated with traditional hormonal contraceptive methods, offering a promising alternative for those seeking safer birth control solutions.

Cayaba Care is a maternal health company focused on providing comprehensive support to medium and high-risk women throughout their pregnancy and postpartum journeys. The company employs a multidisciplinary approach, utilizing Maternity Navigators who are also certified doulas, to partner with members and enhance birth outcomes. Cayaba Care's services address a range of pregnancy-related concerns, including symptom relief, mental health support, breastfeeding assistance, and postpartum follow-up. By offering both virtual and in-person care, the company aims to alleviate stress and anxiety associated with pregnancy, ensuring that women experience a healthy and safe journey. Cayaba Care collaborates with commercial and Medicaid plans to implement standard and value-based care contracts, ultimately improving care quality and patient experience while achieving significant cost savings.

Fogarty Innovation is a nonprofit organization based in Mountain View, California, focused on advancing medical innovation to enhance human health. Founded in 2007, the organization supports promising innovators and researchers by transforming their creative ideas into practical solutions that improve patient care. It operates as an incubator, providing essential funding, mentorship, and research tools to facilitate the development of medical concepts from inception to application. Fogarty Innovation offers two key programs: one aimed at fostering innovation for startups and another dedicated to educating the next generation of inventors. Through these initiatives, Fogarty Innovation coordinates access to vital intellectual, physical, and financial resources to drive medical advancements.

Raydiant Oximetry, Inc. is a medical device company established in 2015 and headquartered in Mountain View, California. The company specializes in the development of a low-cost, non-invasive device that monitors fetal oxygen levels during labor, with the aim of improving health outcomes for mothers and their babies. By providing real-time data on fetal oxygenation, Raydiant Oximetry's technology seeks to enhance patient care, reduce the occurrence of unnecessary cesarean sections, and lower healthcare costs associated with childbirth. The company's innovations are designed to address potential birth injuries and minimize over-intervention in the delivery process, ultimately striving to improve the overall experience and safety of childbirth.

Testmate Health is a medtech startup and an award-winning spin-off from the University of Geneva, Switzerland. The company has developed a smartphone-compatible platform that offers a test kit capable of diagnosing diseases with identifiable DNA or RNA sequences without laboratory involvement, providing rapid results at home in minutes. Their initial product is a user-friendly, all-in-one kit that serves as the first rapid urine self-test for the four most common sexually transmitted diseases (STDs). Given that one million new STDs are diagnosed daily, Testmate Health addresses a critical gap in the market, as traditional testing often requires lab processing and can take up to a week for results. The kit not only delivers immediate results but also allows users to scan their results with a smartphone, facilitating quick access to treatment if necessary. Additionally, Testmate Health has plans to expand its offerings with test kits for other diseases, empowering individuals to manage their health conveniently from home.

Contraline, Inc. is a biotechnology company based in Charlottesville, Virginia, focused on developing innovative male birth control solutions. The company is pioneering the first long-lasting, non-hormonal, and reversible contraceptive for men. Its primary product, Echo-V, is an ultrasound-visible polymer solution that is injected into the vas deferens, forming a polymer hydrogel device. This device functions as a semi-permeable membrane, effectively blocking sperm while allowing bodily fluids to pass through. Contraline also offers Vasintomy, a non-surgical procedure for the insertion of Echo-V, providing a cost-effective and accessible approach to male contraception. Incorporated in 2015, Contraline aims to transform the landscape of reproductive health for men.

Mae is a women's health care center providing pregnancy and postpartum support, tailored to women's needs. Mae is establishing a world in which high-quality, proactive care is the norm. Mae improves the quality of care for Black women by providing a trusted, digital-first health platform.

OCON Healthcare, also known as OCON Medical Ltd., specializes in developing and manufacturing innovative women's health products centered around its proprietary Intra Uterine Ball (IUB) platform. Key offerings include the IUB Ballerine, a hormone-free, copper-based intrauterine contraceptive effective for five years, and the OCON SEAD, which is currently undergoing Phase II clinical studies for treating abnormal uterine bleeding. The IUB platform, constructed from a super-elastic alloy, serves as an effective carrier for various therapeutic substances targeting conditions such as heavy menstrual bleeding, fibroids, and infertility. The company distributes its contraceptive products primarily in Europe, South Africa, and Israel. Founded in 2011, OCON Healthcare operates from its headquarters in Modi'in-Maccabim-Re'ut, Israel, and maintains an additional office in Zürich, Switzerland.

Cirqle Biomedical is a Copenhagen-based biotech company focused on advancing women's health through innovative contraceptive solutions. The company is developing a non-hormonal contraceptive technology that utilizes mucus engineering principles to create a temporary barrier in cervical mucus, preventing sperm from entering the uterus. This approach aims to provide women with greater control over their reproductive choices without the use of traditional hormonal methods. By prioritizing women's freedom and quality of life, Cirqle Biomedical seeks to transform contraceptive options and enhance reproductive health.